AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned a $69.00 price objective by research analysts at Robert W. Baird in a report issued on Wednesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Robert W. Baird’s price objective would indicate a potential downside of 2.54% from the company’s previous close.

A number of other brokerages have also weighed in on ANAB. JMP Securities raised their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a report on Tuesday. Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. Credit Suisse Group raised their price target on shares of AnaptysBio from $38.00 to $85.00 in a report on Tuesday. Finally, Royal Bank Of Canada started coverage on shares of AnaptysBio in a report on Thursday, September 14th. They issued an “outperform” rating and a $40.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $59.14.

AnaptysBio (NASDAQ:ANAB) traded down 3.16% during midday trading on Wednesday, reaching $68.56. The company’s stock had a trading volume of 1,018,201 shares. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $74.00. The firm has a 50-day moving average price of $38.75 and a 200 day moving average price of $38.75. The stock’s market capitalization is $1.39 billion.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $3.45 million. Equities research analysts predict that AnaptysBio will post ($1.99) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “AnaptysBio, Inc. (ANAB) Given a $69.00 Price Target by Robert W. Baird Analysts” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/13/anaptysbio-inc-anab-given-a-69-00-price-target-by-robert-w-baird-analysts.html.

In other AnaptysBio news, major shareholder Holdings A/S Novo sold 70,706 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total value of $1,648,156.86. Following the transaction, the insider now directly owns 3,009,949 shares of the company’s stock, valued at $70,161,911.19. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,133,940 shares of company stock worth $24,223,316.

A number of hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new position in AnaptysBio in the first quarter valued at approximately $24,474,000. Artal Group S.A. boosted its stake in AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after acquiring an additional 205,310 shares during the last quarter. Marshall Wace North America L.P. bought a new position in AnaptysBio in the first quarter valued at approximately $6,924,000. MARSHALL WACE ASIA Ltd bought a new position in AnaptysBio in the first quarter valued at approximately $6,924,000. Finally, Vanguard Group Inc. boosted its stake in AnaptysBio by 22.6% in the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock valued at $4,931,000 after acquiring an additional 37,932 shares during the last quarter. 71.35% of the stock is currently owned by hedge funds and other institutional investors.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.